Aluna

Aluna is a San Francisco-based respiratory management company that makes a portable, FDA-cleared digital spirometer paired with a mobile application and a clinician-facing dashboard. Patients blow into the pocket-sized device, which connects to a phone over Bluetooth and charges via USB, to perform a spirometry maneuver at home or on the go. The app records FEV1% over time and lets users log medications, respiratory symptoms, exercise and environmental factors, then share up to three months of data with a healthcare provider by email; for prescribed users, readings upload automatically to Aluna's server for provider review.

On the clinical side, Aluna provides a portal in which physicians can view all of their patients, filter by attributes, receive automatic flags for at-risk patients through real-time data sync, and sort tasks by billing code while tracking time per patient. Beyond FEV1% and PEF, providers can access flow-volume curves, environmental factors, medication usage, respiratory symptoms and exercise activity. The company's algorithms distinguish adequate from inadequate spirometry effort so that clinicians see meaningful readings, and machine-learning models are used to help identify and correct respiratory problems. The product is cleared for both over-the-counter and prescription use in children and adults, and targets asthma, cystic fibrosis and COPD.

The consumer experience is gamified: the app presents lung function as a rocket launch scaled to breath strength, and includes goals, in-app reminders, quests, collectible gems exchangeable for ship parts, achievements, explorable moons and characters in a children's version, intended to encourage daily readings and proper technique.

Founding story

Aluna began after Charvi Shetty took a Biodesign course in her senior year at UC Berkeley and recruited a friend, Inderjit "Indy" Jutla, to help turn her research into a portable pediatric respiratory management tool. Jutla had asthma as a child, and the founders deliberately focused on children, noting that children make up about a quarter of the asthma population but account for almost half of asthma emergencies and hospitalizations. After building and testing the first prototype, Shetty discovered she had limited respiratory function and was subsequently diagnosed with asthma. Shetty holds a BA in bioengineering from UC Berkeley and a master's in biomedical imaging from UC San Francisco; Jutla holds double degrees in materials science and computer science from UC Berkeley.

Business model

Aluna sold an FDA-cleared digital spirometer paired with a mobile app and a provider-facing dashboard, serving both direct-to-patient (over-the-counter) and clinician-prescribed channels. For healthcare providers, the platform was positioned as a remote patient monitoring service: clinicians onboard patients, monitor adherence and alerts through a portal, and use Aluna's time-tracking tool to bill against CPT codes. The platform was described as eligible for insurance coverage under Remote Patient Monitoring.

Revenue derives from sales of the spirometer device and app to patients and from provider-oriented programs and packages, with clinicians able to generate reimbursement by billing remote patient monitoring CPT codes using Aluna's time-tracking tool; the platform is also eligible for insurance coverage under Remote Patient Monitoring.

Traction

Reported 4,000 active users across the U.S. as of March 2023 and $27M raised in total funding. Following the Huma acquisition, the technology was positioned to reach more than 150 U.S. health systems and over 500,000 contracted lives. The company cites peer-reviewed and NSF-published research on self-management, medication adherence and home spirometry monitoring.

Latest developments

In May 2025 Huma announced the acquisition of Aluna, integrating its respiratory monitoring tools into the Huma Cloud Platform to expand chronic respiratory care across more than 150 U.S. health systems covering over 500,000 contracted lives; the relaunch of Aluna's technology on Huma's platform was said to elevate its regulatory status to FDA Class II. Huma announced the deal alongside a partnership with Eckuity Capital to support a broader M&A strategy.